E. David Crawford, MD, presented “Screening for Prostate Cancer: PSA: Why 1.5 is the New 4.0” during the 24th Annual Southwest Prostate Cancer Symposium on April 11, 2019 in Scottsdale, Arizona.
How to cite: Crawford, E. David “Screening for Prostate Cancer: PSA: Why 1.5 is the New 4.0” April 11, 2019. Accessed May 2021. https://dev.grandroundsinurology.com/screening-for-prostate-cancer-psa-why-1-5-is-the-new-4-0/
Screening for Prostate Cancer: PSA: Why 1.5 is the New 4.0 – Summary:
E. David Crawford, MD, argues for using PSA levels of 1.5 ng/mL as the cutoff point for determining prostate cancer risk in routine screening. He discusses the need for utilizing better risk-assessment methods for detecting prostate cancer, such as genomic markers, in order to reduce unnecessary biopsies, over-detection of indolent disease, and reliance on PSA testing alone.
About the Southwest Prostate Cancer Symposium
The Southwest Prostate Cancer Symposium (SPCS) is a multi-day conference that seeks to educate urologists, radiation oncologists, medical oncologists, and other healthcare professionals involved in the treatment of prostate cancer. The topics focus on current technical aspects of diagnosis and treatment of localized and advanced disease, particularly regarding imaging, technology, and training in the related devices. Dr. Crawford presented this lecture during the 24th SPCS in 2019. In 2020, the 25th SPCS will also offer training sessions involving imaging, scanning, and prostate cancer treatment related devices on site. Please visit this page in order to register for future SPCS meetings.